일일 뉴스

A pharmacist from Na‑mu Pharmacy explains that waxing may cause temporary redness or inflammation and recommends immediate cooling and moisturising.

Cooler mornings prompt people to restart walking, running, and hiking, but sudden activity after a break can strain knee joints and cause pain or swelling.

The article highlights pharmacists’ extensive duties—from prescription verification to inventory and patient interactions—while emphasizing their professional judgment and economic pressures.

South Korea's Pharmaceutical Association will expand its pharmacy‑based crisis‑household detection pilot from Seoul to all pharmacies nationwide on Sept 1, partnering with the Korea Social Security Information Service.

Pharmacy students have formed the ‘Hope Pharmacy Leaders Volunteer Group’ to provide care for South Korea’s growing population of elderly living alone, amid high poverty and suicide rates.

Daewoong Pharmaceutical was honored with the inaugural Seoul BioHealth Award for its expanded new‑drug pipeline and open‑innovation achievements.

Il-yang Pharmaceutical released 'Wizer Alpha', a high‑dose gastrointestinal tablet that blends multiple digestive enzymes, UDCA and antacid agents to support digestion and neutralize stomach acid.

Baim organized the 2026 Jupiter Gyeongju Symposium at Lahan Select Gyeongju, presenting clinical experiences and procedural strategies for the PDLLA‑based bio‑stimulator JUVELOOK.

Celltrion's board approved a 1 trillion KRW share repurchase of 524,384 shares, part of a policy to return one‑third of annual net profit to shareholders.

The Gyeonggi‑do Pharmaceutical Association and its Women’s Pharmaceutical Committee handed over medicines worth about 6 million won for South Sudan, scheduled to depart in September and arrive by Christmas.

COVID‑19 indicators are climbing in Taiwan, China and Korea, leading experts to call for renewed focus on testing and treatment timing for elderly and comorbid patients.

The European Society of Cardiology’s 2026 heart‑failure guideline adds finerenone, an MRA, as a Class I, Level A recommendation for symptomatic HFpEF, alongside SGLT2 inhibitors.